Pulse Biosciences AI Stock Analysis
Want to see PLSE full AI Analyst Report?
Pulse Biosciences (PLSE) AI Stock Analysis
Pulse Biosciences
(NASDAQ:PLSE)
PLSE scores as a mid-range opportunity: strong, upbeat clinical/regulatory progress and a reinforced cash position support the outlook, and price action is trending positively. However, the overall score is held back by very weak current financial performance—large ongoing losses and substantial cash burn relative to a small revenue base—and valuation is constrained by negative earnings.
Pulse Biosciences (PLSE) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $3.30B
- Dividend Yield
- ―
- Average Volume (3M)
- 504.31K
- Price to Earnings (P/E)
- -37.1
- Beta (1Y)
- 0.74
- Revenue Growth
- 1637.21%
- EPS Growth
- -6.34%
- Country
- US
- Employees
- 116
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Instruments & Supplies
Pulse Biosciences Business Overview & Revenue Model
Company Description
Pulse Biosciences, Inc. is an innovative firm specializing in bioelectric medicine. Their primary offering is the CellFX System, a sophisticated, console-based platform that is precisely controlled via software. This system utilizes its proprietary N...
Pulse Biosciences Earnings Call Summary
The call was strongly optimistic, driven by completion of Nano-Pulse AF enrollment three months ahead of schedule, encouraging European efficacy data, substantial financing, expanding clinical programs, and active commercial-readiness investments. The company also reported higher operating losses, expected increases in quarterly spending, limited current commercial revenue, pending pivotal data and regulatory milestones, and remaining manufacturing scale-up work. Overall, the highlights significantly outweighed the lowlights.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management expects final Nano-Pulse AF patient data based on blended 6-month and 12-month follow-up in Q3 2027, anticipates CE Mark approval occurring in Q4 of 2027, and is preparing to support a launch beginning in early 2028; it intends to submit the persistent AF IDE application in the fourth quarter of 2026 and remains on track to complete NANOCLAMP AF enrollment by the end of 1H 2027, with CE Mark approval for the clamp also anticipated in Q4 of 2027. The next-generation nPulse catheter is expected to undergo first-in-human evaluations in 2027, while the Vybrance parathyroid feasibility study will include 15 patients, the PTMC study is designed to enroll up to 30 patients, and additional PRECISE-BTN data are expected during 2027. At scale, gross margins on disposables are anticipated to exceed 70%, and quarterly non-GAAP costs and expenses are expected to increase by 15% to 25% above average Q2 and Q3 levels of approximately $20 million.
Pulse Biosciences Financial Statement Overview
Summary
Financials are dominated by large losses and heavy cash burn despite improving revenue. TTM revenue rose to about $1.5M (+26.1%), but net loss remains very large (about -$83.7M TTM) and operating cash flow/free cash flow are deeply negative (about -$63M TTM). The balance sheet is comparatively supportive with low debt (~$6.4M) versus sizable equity (~$183.6M), but ongoing losses imply continued reliance on external capital if the burn persists.
Income Statement
18Very NegativeBalance Sheet
62PositiveCash Flow
24Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.49M | 350.00K | 0 | 0 | 700.00K | 1.42M |
| Gross Profit | 141.00K | -1.26M | 0 | -1.21M | -11.24M | -550.00K |
| EBITDA | -83.26M | -71.71M | -52.41M | -39.90M | -57.15M | -62.51M |
| Net Income | -83.72M | -72.78M | -53.59M | -42.21M | -58.51M | -63.66M |
Balance Sheet | ||||||
| Total Assets | 201.58M | 94.54M | 132.46M | 59.15M | 77.88M | 54.25M |
| Cash, Cash Equivalents and Short-Term Investments | 189.19M | 80.73M | 118.04M | 44.37M | 61.14M | 28.61M |
| Total Debt | 6.36M | 7.53M | 8.90M | 9.14M | 75.96M | 11.25M |
| Total Liabilities | 18.01M | 13.88M | 17.60M | 14.79M | 80.13M | 18.56M |
| Stockholders Equity | 183.57M | 80.66M | 114.86M | 44.36M | -2.25M | 35.69M |
Cash Flow | ||||||
| Free Cash Flow | -63.70M | -54.44M | -36.47M | -33.16M | -47.41M | -54.53M |
| Operating Cash Flow | -63.33M | -54.12M | -36.34M | -33.04M | -47.01M | -54.10M |
| Investing Cash Flow | -152.72M | -335.00K | -125.00K | -121.00K | -401.00K | 7.56M |
| Financing Cash Flow | 157.56M | 17.15M | 110.14M | 16.39M | 79.94M | 62.69M |
Pulse Biosciences Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PLSE, the sentiment is Negative. The current price of 44.84 is below the 20-day moving average (MA) of 52.85, below the 50-day MA of 51.64, and above the 200-day MA of 33.66, indicating a neutral trend. The MACD of -0.39 indicates Positive momentum. The RSI at 38.38 is Neutral, neither overbought nor oversold. The STOCH value of 5.35 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PLSE.
Pulse Biosciences Risk Analysis
Pulse Biosciences disclosed 61 risk factors in its most recent earnings report. Pulse Biosciences reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksPulse Biosciences Peers Comparison
Overall Rating
ATRC73Outperform
MMSI71Outperform
PLSE60Neutral
TFX57Neutral
ANGO52Neutral
STXS46Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 73Outperform | $2.80B | 183.58 | 2.93% | ― | 13.79% | ― | |
| 71Outperform | $5.06B | 31.49 | 9.65% | ― | 9.34% | 33.77% | |
| 60Neutral | $3.30B | -37.05 | -77.88% | ― | 1637.21% | -6.34% | |
| 57Neutral | $6.33B | 19.24 | 9.74% | 0.85% | -29.30% | ― | |
| 52Neutral | $483.21M | -14.46 | -19.25% | ― | 8.20% | -0.88% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 46Neutral | $88.96M | -3.46 | -115.83% | ― | 4.83% | 15.55% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| PLSE | Pulse Biosciences Inc | 44.84 | 31.83 | 244.66% | |
| ANGO | Angiodynamics, Inc. | 11.49 | -0.41 | -3.45% | |
| ATRC | Atricure, Inc. | 55.02 | 20.84 | 60.97% | |
| MMSI | Merit Medical | 84.49 | 0.80 | 0.96% | |
| STXS | Stereotaxis | 0.88 | -1.36 | -60.62% | |
| TFX | Teleflex | 159.55 | 54.92 | 52.49% |
Pulse Biosciences Corporate Events
Pulse Biosciences Reports Positive Results from Thyroid Nodule Study
PositiveOn November 6, 2026, Pulse Biosciences announced interim six-month results from the PRECISE-BTN study evaluating its nPulse Vybrance system for symptomatic benign thyroid nodules. Among 43 patients assessed, 86% achieved at least 50% nodule-volume re...
Pulse Biosciences partners Clayman Thyroid Center on nsPFA
PositiveOn October 14, 2026, Pulse Biosciences announced a commercial and clinical partnership with the Clayman Thyroid Center at the Hospital for Endocrine Surgery in Tampa, Florida, to deploy the nPulse Vybrance Percutaneous Electrode System in patient car...
Pulse Biosciences Completes Enrollment in NANOPULSE-AF Trial
PositiveOn October 7, 2026, Pulse Biosciences reported it had reached its enrollment goal of 164 evaluable patients in the NANOPULSE-AF IDE pivotal clinical study of its nPulse Cardiac Catheter System for drug-resistant, symptomatic, paroxysmal atrial fibril...
Pulse Biosciences Launches New ATM Equity Program
NeutralOn September 15, 2026, Pulse Biosciences entered into a new equity distribution agreement with Mizuho Securities USA, allowing the company to sell up to $85 million of common stock from time to time in at-the-market and other permitted transactions,...
Pulse Biosciences Completes Enrollment in PRECISE-BTN Study
PositiveOn September 15, 2026, Pulse Biosciences announced it had completed enrollment in its PRECISE-BTN clinical study of the nPulse Vybrance Percutaneous Electrode System for symptomatic benign thyroid nodules, expanding the trial from 50 to 100 patients...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 06, 2026
